• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Tanvex Submits BLA for Proposed Filgrastim Biosimilar

Article

Tanvex BioPharma, a Taiwan-based biopharmaceutical company, announced this week the submission of its Biologics License Application (BLA) to the FDA for TX-01, a proposed filgrastim biosimilar referencing Neupogen.

Tanvex BioPharma, a Taiwan-based biopharmaceutical company, announced this week the submission of its Biologics License Application (BLA) to the FDA for TX-01, a proposed filgrastim biosimilar referencing Neupogen.

Click here to read more about biosimilar filgrastim.

Tanvex announced that it would be seeking the same indications for TX-01 as the reference product is currently approved for: the treatment of chemotherapy-induced neutropenia. According to data from IQVIA, filgrastim sales for Neupogen, Zarxio, and Granix combined were estimated to be $700 million in the United States last year, and Tanvex hopes to capture a share of that market.

“The submission of the BLA for TX-01 represents an exciting milestone for Tanvex. Such a remarkable action takes Tanvex one step closer to launching its very first biosimilar product in the [United States] market,” said Allen Chao, MD, CEO of Tanvex Biopharma.

Tanvex is also in the midst of developing 3 other biosimilars: TX-05, a proposed trastuzumab biosimilar, referencing Herceptin, is currently beginning phase 3 trials for the treatment of HER2-positive breast cancer; TX-16, a potential bevacizumab biosimilar, referencing Avastin, is nearing the conclusion of phase 1 trials and is being investigated for the treatment of metastatic colorectal cancer; and TX-17, a proposed adalimumab biosimilar, referencing Humira, is still in the preclinical phase and is being developed to treat patients with rheumatoid arthritis.

To date, there are 2 filgrastim biosimilars available for use in the United States: Zarxio and Nivestym, the latter of which just recently came to market at a 30.3% discount to the reference product. Though there is a third filgrastim on the market, tbo-filgrastim, sold as Granix, it is not technically a biosimilar due to the fact that it earned FDA approval prior to the creation of the biosimilar approval pathway.

Recent Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Ian Henshaw
Julie M. Reed
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Eric Tichy, PharmD, MBA
Related Content
© 2024 MJH Life Sciences

All rights reserved.